EGLT Profile
Egalet
Corporation (EGLT) is a specialty pharmaceutical company that focuses
on developing and commercializing treatments for pain and other
conditions. The company's primary product is Arymo ER, an
extended-release morphine drug used for the management of pain. Egalet
also develops other products using its proprietary technology
platform, which is designed to create abuse-deterrent products that
are more difficult to manipulate for non-medical purposes.
Egalet was founded in 2010 and is headquartered in Wayne,
Pennsylvania. The company has a strong focus on research and
development, with several drug candidates in various stages of
clinical development. In addition to its proprietary technology
platform, Egalet has also licensed technology from other companies to
support its drug development efforts.
The company faces several
challenges in the highly competitive pharmaceutical industry,
including the need to gain regulatory approval for its products,
establish a market presence, and compete with established players in
the pain management market. Egalet has also faced financial
challenges, with a history of losses and limited financial resources
to support its research and development efforts.
Egalet's stock
is traded on the OTC Markets Group under the ticker symbol EGLT. As
with all OTC stocks, investors should exercise caution and conduct
thorough research before making any investment
|
